Cipla USA, Inc. recalls Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga,

What was recalled

The U.S. Food and Drug Administration has issued a Class II recall affecting a specific batch of prescription medication distributed across the United States. This action involves Cinacalcet Hydrochloride Tablets, specifically the 60 mg strength, packaged in 30-count bottles. The product is marked as "Rx Only," indicating it is available exclusively by prescription and should not be obtained or used without direct medical supervision. While the distribution pattern for this recall is listed as nationwide, the regulatory filing highlights New Jersey (NJ) as a key state associated with the manufacturer’s operational address, though consumers in all 50 states need to verify their bottles against the lot numbers provided below.

The medication was manufactured by Cipla Ltd., located at MIDC in Patalganga, India. However, it was manufactured for and distributed under the brand name of Cipla USA, Inc. The company’s U.S. headquarters is located at 10 Independence Boulevard, Suite 300, Warren, NJ 07059. It is important to distinguish between the manufacturing site in India and the U.S.-based entity responsible for distribution when looking up contact information or reporting adverse events.

To determine if your medication is part of this recall, you must check the National Drug Code (NDC) and the lot number printed on the bottle label. The recalled items bear NDC 69097-411-02. The specific lots included in this recall are 5PB0165, 5PB0166, 5PB0552, 5PB0642, 5PB0643, and 5PB0644. Please note the expiration dates associated with these lots to help identify them: Lots 5PB0165 and 5PB0166 have an expiration date of January 31, 2027. Lot 5PB0552 expires on April 30, 2027. Finally, lots 5PB0642, 5PB0643, and 5PB0644 expire on June 30, 2027. If your bottle matches this NDC and any of the listed lot numbers, it is part of the recall.

The recall was officially announced on June 29, 2026. At this time, the specific remedy for consumers—such as whether they will receive a direct refund, a replacement product, or instructions to return the item—is not stated in the official record. Generally, Class II recalls indicate that use of the product may cause temporary or medically reversible health problems, but are not likely to cause serious adverse health consequences. However, because this involves prescription medication, you should not stop taking your medicine without consulting your healthcare provider. Instead, contact your pharmacist or doctor immediately to discuss how to handle the recall for your specific situation.

The hazard, explained

When we talk about medication safety, most people worry about visible defects like cracked pills or cloudy liquids. However, the issue with this specific recall of Cinacalcet Hydrochloride Tablets is invisible to the naked eye. The U.S. Food and Drug Administration (FDA) has identified a serious manufacturing flaw known as current Good Manufacturing Practice (cGMP) deviations. In plain terms, this means that during the production process at Cipla Ltd., the strict protocols designed to keep drugs pure were not followed closely enough. This oversight allowed an unwanted chemical byproduct to contaminate the medication.

The specific contaminant in question is N-nitroso-cinacalcet. To understand why this matters, it helps to look at how medications are made. Drugs are created through complex chemical reactions. Sometimes, these reactions don’t finish cleanly, or ingredients interact in unexpected ways with other substances present in the factory environment. In this case, a compound called N-nitroso-cinacalcet formed within the tablets. While Cinacalcet itself is a prescribed drug used to treat certain conditions related to calcium levels in the blood, its nitroso derivative is not an active ingredient and has not been approved for safety. The FDA sets what they call an Acceptable Daily Intake (ADI) for such impurities—essentially a threshold below which the risk is considered negligible. The contaminated batches exceed this safe limit.

You might wonder, "What physically happens if I take a pill with too much of this impurity?" Nitroso compounds are generally viewed with high caution in pharmaceutical science because many of them have been shown to be carcinogenic, meaning they can cause cancer, particularly when exposure is significant or prolonged. Even though the risk from a short-term course might be lower than long-term exposure, the principle of safety in medicine is zero tolerance for unapproved impurities above established limits. The body processes these foreign chemicals differently than the intended drug. Instead of regulating calcium, your liver and kidneys have to work overtime to filter out this unwanted substance, potentially causing toxic stress on those organs or leading to cellular damage over time.

It is important to clarify that this hazard is not about the pill failing to work (efficacy), but about it actively becoming harmful (toxicity). The Cinacalcet itself may still be doing its job, but you are simultaneously ingesting a chemical agent that the FDA has determined is unsafe at these levels. Because the contamination occurred during manufacturing, every single tablet in the affected lots contains this impurity. There is no way to "shake off" or separate the bad from the good once it is mixed into the solid matrix of the tablet. This is why the recall is necessary: to remove a hidden, systemic risk from your body before any long-term harm can occur.

While the immediate physical symptoms of ingesting this impurity might not be obvious right away—unlike an allergic reaction that causes swelling or hives—the danger is cumulative. This is why regulatory bodies take cGMP deviations so seriously. They are not just bureaucratic hurdles; they are the final line of defense ensuring that what you put into your body is exactly what was promised, and nothing more. In this case, the "something more" is a chemical impurity that violates safety standards, turning a treatment into a potential health risk.

Who is most at risk

To understand who is most vulnerable in this specific recall, we first need to look at what Cinacalcet actually does for the people taking it. This prescription medication is primarily prescribed to manage hyperparathyroidism, a condition where the parathyroid glands produce too much parathyroid hormone (PTH). This excess hormone disrupts the delicate balance of calcium in the blood, often leading to dangerously high levels. Consequently, the people taking Cinacalcet are typically adults who are managing complex endocrine disorders. These individuals are not just dealing with a simple vitamin deficiency; they are managing a chronic condition that affects bone health and can lead to serious complications like kidney stones or bone pain if left uncontrolled. Because the drug works by altering how the body senses calcium levels, it has a narrow therapeutic window. This means that even small variations in the concentration of the medication can have outsized effects on the patient’s physiology.

The specific hazard here involves N-nitroso-cinacalcet, a potential carcinogen found above acceptable limits due to current Good Manufacturing Practice (cGMP) deviations. While the immediate danger of a single dose might be difficult to quantify without medical context, the primary risk profile for this recall centers on long-term exposure rather than acute toxicity. This distinction is crucial. For a healthy adult taking a medication occasionally, the risk calculus is different than for someone who has been taking this specific batch daily for months or years. The individuals most at risk are those who have consumed significant quantities of the affected lots (5PB0165, 5PB0166, 5PB0552, 5PB0642, 5PB0643, and 5PB0644) over an extended period. The concern is not that the drug will stop working today, but that the cumulative exposure to this impurity may increase long-term health risks associated with nitroso compounds.

While the FDA classification is Class II, indicating that use of or exposure to the product might cause temporary health problems or pose slight threat of serious nature, we must consider the physiological fragility of certain patient groups. Patients with hyperparathyroidism often have concurrent health issues, particularly related to kidney function and bone density. The kidneys play a central role in filtering toxins and managing mineral balance. If a patient has pre-existing renal impairment—a common comorbidity with severe hyperparathyroidism—their body’s ability to process and eliminate unwanted substances may already be compromised. This makes them potentially more susceptible to the effects of any impurity present in their medication.

Furthermore, we must consider the elderly population, who are statistically more likely to suffer from secondary hyperparathyroidism due to chronic kidney disease. Older adults often take multiple medications (polypharmacy), which can complicate how their bodies metabolize drugs and impurities. While Cinacalcet itself is not sedative or immediately incapacitating, the underlying anxiety of having consumed a contaminated drug can be significant for those who rely on it to maintain their quality of life and prevent hospitalization. Therefore, the "most at risk" group is not defined by age alone, but by the duration of exposure to the specific contaminated lots and the existing fragility of the patient’s metabolic and renal systems.

It is also important to note that this recall affects a nationwide distribution pattern, meaning there is no geographic buffer. Whether you are in New Jersey or anywhere else in the United States, if you have these specific lot numbers, your risk profile is identical. The 30-count bottles were distributed widely, so the likelihood of having an unused or partially used bottle from this batch is real for many patients. This widespread distribution amplifies the importance of checking your specific prescription, as the risk is not isolated to a single clinic or region but is spread across the general population of hyperparathyroidism patients.

How to tell if you have the recalled item

Verifying whether your medication is part of this recall requires a careful, methodical check of your prescription bottle. Because this issue involves specific manufacturing batches from Cipla USA, Inc., simply having "Cinacalcet Hydrochloride" in your medicine cabinet is not enough to confirm the risk. You must look for several precise identifiers printed on the label. The first step is to confirm the brand and manufacturer details. Look closely at the packaging to ensure the product is labeled as Cipla and manufactured by Cipla Ltd. located in MIDC, Patalganga, India, for Cipla USA, Inc. in Warren, NJ. If your bottle bears a different manufacturer’s name or logo, it is not part of this specific recall notice.

The most critical piece of information you need to check is the National Drug Code (NDC) and the Lot Number. These codes are unique identifiers that link your specific bottle to the affected production runs. The recalled product is exclusively NDC 69097-411-02. If your bottle has a different NDC, it is not included in this recall. Next, you must locate the Lot Number, which is typically printed on the side or back of the label near the expiration date. The FDA has identified the following specific lot numbers as part of this Class II recall:

• 5PB0165
• 5PB0166
• 5PB0552
• 5PB0642
• 5PB0643
• 5PB0644

It is also important to verify the strength and package size of the medication. This recall applies specifically to Cinacalcet Hydrochloride Tablets, 60 mg, packed in a 30-count bottle. If you have a different dosage (such as 30 mg or 90 mg) or a different package count (such as a 60-count bottle), it is not part of this recall. Additionally, check the expiration dates associated with the lot numbers you found earlier to ensure they match the timeline of the affected batches:

• Lots 5PB0165 and 5PB0166 expire on 1/31/2027.
• Lot 5PB0552 expires on 4/30/2027.
• Lots 5PB0642, 5PB0643, and 5PB0644 expire on 6/30/2027.

If you have a bottle that matches the brand (Cipla), the NDC (69097-411-02), the specific lot number listed above, and the 60 mg strength, you have one of the recalled items. If you are unsure or cannot find the lot number, it is safest to contact your pharmacist immediately. They can scan the barcode on your bottle and verify whether it falls within the affected distribution pattern, which was nationwide across the United States as of the recall date of June 29, 2026.

What to do — step by step

If you currently possess the recalled Cinacalcet Hydrochloride Tablets manufactured by Cipla Ltd. and distributed by Cipla USA, Inc., it is important to approach this situation with calm diligence rather than panic. The U.S. Food and Drug Administration (FDA) has classified this as a Class II recall, which typically indicates a situation where use of the product could cause temporary health problems or pose a slight threat of a serious nature. While the specific remedy details such as return addresses or direct refund procedures are not explicitly stated in the current FDA report, the standard protocol for pharmaceutical recalls involving potential chemical contamination requires immediate action on your part to ensure your safety.

1. Stop taking the medication immediately. The primary hazard identified in this recall is the presence of N-nitroso-cinacalcet, a substance that exceeds the acceptable daily intake (ADI) limits. This deviation from current Good Manufacturing Practices (cGMP) means the drug’s purity and safety profile are compromised. Do not wait for a refill or try to finish the bottle. Continuing to take this medication exposes you to unnecessary chemical risks that outweigh the benefits of treating your condition temporarily.
2. Identify your specific lot numbers. To confirm whether your bottles are part of this recall, you must check the packaging carefully. This recall affects Cinacalcet Hydrochloride Tablets, 60 mg, in 30-count bottles with the National Drug Code (NDC) 69097-411-02. You need to look for the following specific lot numbers on your bottle label: 5PB0165, 5PB0166, 5PB0552, 5PB0642, 5PB0643, and 5PB0644. Verify the expiration dates as well; lots 5PB0165 and 5PB0166 expire on January 31, 2027; lot 5PB0552 expires on April 30, 2027; and lots 5PB0642, 5PB0643, and 5PB0644 expire on June 30, 2027. If your lot number does not match these exactly, your medication is likely safe and not part of this specific recall.
3. Contact your healthcare provider or pharmacist right away. Since you have stopped taking a prescription medication, you need professional medical guidance to manage any potential withdrawal effects or gaps in treatment. Call the pharmacist who filled your prescription or your prescribing doctor immediately. They can advise you on whether you need an alternative medication to bridge the gap until you can obtain a safe replacement. Do not attempt to self-medicate with leftover supplies from other bottles unless explicitly directed by your doctor.
4. Arrange for the proper disposal or return of the recalled product. Because the FDA report does not list a specific return address or mail-in form, do not simply throw the pills in the household trash without precautions. Contact your local pharmacy where you purchased the drug; they often have take-back programs or can direct you to authorized hazardous waste disposal facilities. Alternatively, check the Cipla USA, Inc. website or their customer service line for specific instructions on how to return the defective product for analysis or credit. Keep the bottle and its label intact until you have received these instructions, as they serve as proof of purchase and lot identification.
5. Monitor your health closely. While the risk is defined by the potential exposure to N-nitroso-cinacalcet, be vigilant for any unusual symptoms. If you experience any adverse effects after taking the recalled drug, report them to your healthcare provider immediately. Furthermore, consider reporting any side effects to the FDA MedWatch program online or by phone. This helps health authorities track the real-world impact of the recall and ensures that other patients are protected.

Remember, this process is about managing a known risk efficiently. By stopping use, verifying your lot numbers, and consulting your medical team, you take full control of your health safety during this administrative and medical transition.

Your refund, repair, or replacement options

When a medication recall occurs, the most immediate question on your mind is likely, "What do I do with my pills, and how do I get my money back?" It is completely normal to feel a mix of frustration and concern in this situation. Please take a deep breath. While the recall announced by the Food and Drug Administration (FDA) regarding Cipla USA, Inc.’s Cinacalcet Hydrochloride Tablets is serious due to manufacturing quality issues, the path forward for consumers is designed to be straightforward, even if the specific details here require a bit of patience.

The first thing you need to know is that the official recall facts do not explicitly list a specific remedy in terms of financial restitution. The record states "not stated" regarding the remedy. This means there is no pre-written script or guaranteed automatic refund process outlined in the public notification. However, this does not mean you are left without recourse. In these scenarios, the standard and most effective course of action is to contact the source where you purchased the medication directly. Your pharmacy or healthcare provider is your primary ally here.

If you bought these tablets at a retail pharmacy, such as a local drugstore chain or an independent shop, you should call their customer service or speak with the pharmacist on duty. Explain that you have product from the recalled lots and ask for a full refund. Most reputable pharmacies have protocols in place to handle recalled items without question. They will typically accept the returned product back and issue a credit to your original payment method or provide cash if it was a cash purchase. Do not worry about the physical condition of the bottle; they are equipped to handle the disposal of the medication safely.

If you purchased the medication through a mail-order service or an online pharmacy, the process is similar but may take slightly longer. You should contact their customer support team immediately. They will likely provide you with a return shipping label and instructions on where to send the unused portion of your medication. Once they receive it, they will process the refund. Keep in mind that because the remedy terms are not explicitly defined in the FDA notice, you may need to rely on the specific policies of the retailer you used. It is crucial to act promptly so you are not left with a medication that is no longer safe for use.

In some cases, particularly if you have already started taking the medication or if the recall impacts a critical treatment plan, it is wise to also consult your prescribing doctor. While they cannot process your refund, they can help coordinate with your pharmacy to ensure you do not experience any gaps in your care. They might be able to authorize a replacement from a different manufacturer or lot number that is not affected by this cGMP deviation. This ensures your health remains the priority while the financial side is sorted out separately.

It is important to remember that you are not responsible for the manufacturing errors that led to the presence of N-nitroso-cinacalcet above acceptable limits. You did nothing wrong by purchasing or using the product before the recall was announced. Your goal now is simply to remove the potentially contaminated medication from your home and recover your funds. By contacting your pharmacy or retailer directly, you are taking the correct steps to resolve this issue efficiently. Do not hesitate to ask for a manager if you encounter any resistance; recalls are taken very seriously in the healthcare industry, and they want to make this right for you.

What can happen if you ignore it

Staying safe: broader tips

Maintaining safety with prescription medications requires a proactive approach that extends far beyond reacting to specific alerts. While this recall highlights a manufacturing deviation regarding impurity levels, the broader lesson for consumers is the importance of understanding how pharmaceutical quality is maintained and how you can advocate for your own health security. Medications are complex chemical compounds, and even minor deviations in the production environment—such as contamination or improper processing conditions—can affect their safety profile. This is why regulatory agencies like the FDA rely on Current Good Manufacturing Practices (cGMP) to ensure that every batch leaving a facility meets strict purity and potency standards. As a consumer, you may not have direct access to the manufacturing floor, but you do have power through vigilance and informed habits.

One of the most effective ways to stay safe is to establish a routine for monitoring your medications. Keep a simple log or digital record of the drugs you take, including their National Drug Code (NDC), lot numbers, and expiration dates. This information is typically printed on the pharmacy label or the bottle itself. By keeping these details organized, you eliminate the stress and confusion during a recall event. When an alert is issued, you can quickly verify if your specific bottles are affected without having to dig through cabinets or contact multiple pharmacies for confirmation. This organizational habit also helps you avoid taking expired medications, which can lose efficacy or degrade into unknown compounds over time.

Furthermore, consider setting up automated alerts from reliable sources such as the FDA’s website, your healthcare provider’s patient portal, or reputable health news outlets. These channels often provide context that goes beyond a simple list of products. Understanding the nature of the hazard—whether it is a microbial contamination, a labeling error, or a chemical impurity—helps you assess your personal risk accurately. For instance, while some hazards require immediate discontinuation, others may allow for a gradual transition to an alternative under medical supervision. Always consult your pharmacist or physician before making any changes to your medication regimen, as sudden stops can sometimes be more dangerous than the product itself.

Finally, foster an open line of communication with your healthcare team. If you have questions about manufacturing origins, such as knowing that a drug was produced in a specific facility like Cipla Ltd., do not hesitate to ask your pharmacist for clarification. They can provide insights into supply chain reliability and alternative options if needed. Building this relationship ensures that you are never left guessing when safety issues arise, empowering you to make confident, informed decisions about your health.